Oligonucleotide-based gene therapy for cardiovascular disease

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 8, 1998, Pages 529-534

  Morishita, Ryuichi ^a   Nakagami, Hidenori ^a   Taniyama, Yoshiaki ^a   Matsushita, Hidetsugu ^a   Yamamoto, Kei ^a   Tomita, Naruya ^a   Moriguchi, Atsushi ^a   Matsumoto, Keiko ^a   Higaki, Jitsuo ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antisense; cis Element decoy; Hemagglutinating; Infarction; Myocardial; Restenosis; Virus of Japan (HVJ) liposome method

Indexed keywords

OLIGONUCLEOTIDE;

ANGIOPLASTY; BLOOD VESSEL SHUNT; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CYSTIC FIBROSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENE THERAPY; GENE TRANSFER; GRAFT OCCLUSION; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RESTENOSIS; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; GENE THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0031698136     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1998.090     Document Type: Conference Paper

References (53)

1. Isner JM. Oligonucleotide therapeutics - novel cardiovascular targets. Nat Med 1997; 3:834-5.
2. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988; 48:2659-68.
3. Dzau VJ. Morishita R, Gibbons GH. Gene therapy in the cardiovascular diseases. Trends Biotechnol 1993; 11:205-10.
4. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82:1023-28.
5. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation 1992; 86:III-47-52.
6. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol 1989; 14:S12-5.
7. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-8.
8. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358:259-61.
9. Pagano M, Draetta G, Durr J. Association of cdk 2 kinase with the transcription factor E2F during S phase. Science 1992; 255:1144-7.
10. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90:8474-9.
11. Morishita R, Gibbons, GH, Ellison KE, Nakajima M, Leyen HVL, Zhang L, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides J Clin Invest 1994; 93:1458-64.
12. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall: enhanced therapeutic utility for restenosis by HVJ-liposome method. Gene 1994; 149:13-9.
13. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVL, Zang L, et al. Antisense oligonucleotides directed at cell cycle regulatory genes as a target for restenosis therapy. Trans Assoc Am Physicians 1993; 106:54-61.
14. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359:67-80.
15. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermami P, Dodge GR, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90:944-51.
16. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeocynucleotides. J Clin Invest 1994; 93:820-8.
17. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, et al. Genetic engineering of vein grafts resistant to atherosclerosis, proc. Natl Acad Sci USA 1995; 92:4502-6.
18. Mann MJ, Gibbons GH, Tsao PS, von-der Leyen HE, Cooke JP, Buitrago R, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997; 99:1295-301.
19. Suzuki J, Isobe M, Morishita R, Aoki M, Horie S, Okubo Y, et al. Prevention of graft coronary arteriosclerosis by antisense cdk 2 kinase oligonucleotides. Nat Med 1997; 3:900-3.
20. Bielineska A, Shivdasani RA, Zhang L, Nael GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250:997-1000.
21. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, et al. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92:5855-9.
22. Morsihita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, et al. In vivo transfection of cis element "decoy" against NFκB binding site prevented myocardial infarction as gene therapy. Nat Med 1997; 3:894-9.
23. Sawa Y, Morishata R, Suzuki K, Kagisaki K, Kaneda Y, Maeda K, et al. A novel strategy for myocardial protetion using in vivo transfection of cis element "decoy" against NFκB binding site: evidence for a role of NFκB in ischemic-reperfusion injury. Circulation 1997; 965:II-280-5.
24. Tomita N, Kim J, Gibbons GH, Baran D, Ogborn M, Stahl RAK, et al. In vivo gene therapy of anti-Thy 1 nephritis using E2F decoy oligonucleotides [abstract]. J Am Soc Nephrol 1995; 6:887.
25. Tomita N, Morishita R, Higaki J, Kaneda Y, Ogihara T. Potential gene therapy to glomerular disease: application of transcriptional factor decoy approach [abstract]. Nephrology 1997; 3:S33.
26. Morishita R, Higaki J, Tomita N, Aoki M, Moriguchi A, Tamura K, et al. Role of transcriptional cis-elements, angiotensinogen gene-activating element, of angiotensinogen gene in blood pressure regulation. Hypertension 1996; 27:502-7.
27. Yamada T, Horiuchi M, Morishita R, Zhang L, Pratt RE, Dzau VJ. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. J Clin Invest 1995; 96:1230-7.
28. Lenardo MJ, Baltimore D, NV-kappa B: a pleitoropic mediator of inducible and tissue-specific gene control. Cell 1989; 58:227-9.
29. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NFκB transcritpion factor. Mol Cell Biol 1990; 10:2327-34.
30. Satriano J, Schlondorff. Activation of attenuation of transcriptional factor NFκB in mouse glomerula cells in response to tumor necrosis factor-α, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate. J Clin Invest 1994; 94:1629-36.
31. Chow J, Hartley RB, Jagger C, Dilly SA. ICAM-1 expression in renal disease. J Clin Pathol 1992; 45:880-4.
32. Floege J, Eng E, Young BA, Johnson R. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int 1993; 39:547-S54.
33. Sterzel RB, Schulze-Lohoff E, Marx M. Cytokines and mesangial cells. Kidney Int 1993; 39:S26-S31.
34. Egido J, Gomez-Chiarri M. Ortiz A, Bustos C, Alonso J, Gomez-Guerrero, et al. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. Kidney Int 1993; 39:S59-S64.
35. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postichemic/reperfused myocardium. Am J Pathol 1995; 146:419-28.
36. Kukielka GL, Smith CW, LaRosa GJ, Manning AM, Mendoza LH, Daly TJ, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995; 95:89-103.
37. Kukielka GL, Entman ML. Adhesion molecule-dependent cardiovascular injury. In: Poste G, Metcalf B, editors. Cellular adhesion: molecular definition to therapeutic potential. New York: Plenum Publishing Corp 1994, 187-212.
38. Brennan DC, Jevnikar AM, Takei F, Reubin-Kelley VE. Mesangial cell accessory functions: mediation by intracellular adhesion molecule-1. Kindney Int 1990; 38:1039-46.
39. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 1992; 175:1583-93.
40. Chu BC, Orgel LE. The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 1992; 20:5857-8.
41. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989; 243:375-8.
42. Morishita R, Gibbons GH, Horiuchi M, Nakajima M, Ellison KE, Lee W, et al. Molecular delivery system for antisense oligonucleotides: enhanced effectiveness of antisense oligonucleotides by HVJ-liposome mediated transfer. J Cardiovas Pharmacol Ther 1996; 2:213-22.
43. Gibson I. Antisense approaches to the gene therapy of cancer-'Recnac'. Cancer Metastasis Rev 1996; 15:287-99.
44. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1996; 24:737-75.
45. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995; 92:4051-5.
46. Srinivasan SK, Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 1995; 9:129-139.
47. Henry SP, Bolte H, Auletta C, Kornbrust DJ. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 1997; 120:145-55.
48. Cornish KG, Iversen P, Smith L, Arneson M, Bayever E. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Comm 1993; 3:239.
49. Henry SP, Gicals PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997; 281:810-6.
50. Crooke ST. Progress in antisense therapeutics. Hematol Pathol 1995; 9:59-72.
51. Anderson WF. Human gene therapy. Science 1992; 256:808-13.
52. Miller AD. Human gene therapy comes of age. Nature 1992; 357:455-60.
53. Mann MJ, Whittemore AD, Donaldson MC, Belkin MA, Orav EJ, Polak J, Dzau VJ. Preliminary clinical experience with genetic engineering of human vein grafts: evidence for target gene inhibition. [abstract]. Circulation 1997; 96:I-4.